全体要約
腫瘍壊死因子阻害薬市場は、2023年に数百万米ドルと推定され、2030年までに同額に調整される見込みで、2024年から2030年の予測期間中にCAGRは%となる。
北米市場は2023年に数百万米ドルで、2030年には同額に達し、CAGRは%である。アジア太平洋市場と欧州市場も同様の成長が見込まれている。
主要企業にはAbbVie、Amgen、Johnson & Johnson、UCB、Novartis、Pfizer、Merck、CASI Pharmaceuticals、EPIRUS Biopharmaceuticalsなどがあり、2023年には上位5社が収益の約%を占めている。市場は、リウマチ性関節炎、乾癬性関節炎、クローン病などのアプリケーションに分かれている。
関連する質問
AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB, Novartis AG, Pfizer, Inc., Merck & Co., Inc., CASI Pharmaceuticals, EPIRUS Biopharmaceuticals
腫瘍壊死因子に対する生物学的治療の需要増加, 新しい治療法の開発, 既存治療の効果向上
概要
2023年の腫瘍壊死因子阻害薬の世界市場は、XX米ドルと見積もられており、2030年までにXX米ドルに再調整されると予測されています。2024年から2030年の予測期間中の年平均成長率（CAGR）はXX%です。
2023年の北アメリカにおける腫瘍壊死因子阻害薬市場は$百万の評価を受け、2030年までに$百万に達する見込みで、2024年から2030年までの予測期間中にXX%のCAGRを記録します。
アジア太平洋地域の腫瘍壊死因子阻害剤市場は、2023年にドルの価値があり、2030年までにドルに達すると予想されており、2024年から2030年の予測期間中にXX%のCAGRで成長する見込みです。
2023年の欧州における腫瘍壊死因子阻害薬の市場は、$百万の価値があり、2030年までに$百万に達する見込みです。予測期間である2024年から2030年の間、年平均成長率（CAGR）はXX%です。
腫瘍壊死因子阻害薬の世界の主要企業には、アッヴィ（AbbVie Inc.）、アムジェン（Amgen Inc.）、ジョンソン・エンド・ジョンソン（Johnson & Johnson）、UCB、ノバルティス（Novartis AG）、ファイザー（Pfizer, Inc.）、メルク（Merck & Co., Inc.）、CASIファーマシューティカルズ、エピルスバイオファーマシューティカルズ（EPIRUS Biopharmaceuticals）などが含まれています。2023年には、世界の上位5社が収益において約XX%のシェアを持っています。
レポート範囲
この報告書は、腫瘍壊死因子阻害薬の世界市場に関する包括的なプレゼンテーションを提供することを目的としており、総販売量、売上高、価格、主要企業の市場シェアとランキング、ならびに地域・国別、タイプ別、アプリケーション別の腫瘍壊死因子阻害薬の分析を行います。
腫瘍壊死因子阻害薬市場の規模、推定、予測は、2023年を基準年とし、2019年から2030年までの期間に関する過去のデータと予測データを考慮して、販売量（Kユニット）および売上高（百万ドル）で提供されます。定量的および定性的な分析を通じて、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社の位置を分析し、腫瘍壊死因子阻害薬に関する情報に基づいたビジネス意思決定を行うのに役立てることを目的としています。
市場セグメンテーション
会社別
アッヴィ株式会社
アムジェン社
ジョンソン・エンド・ジョンソン
UCB
ノバルティス AG
ファイザー株式会社
メルク・アンド・カンパニー社
CASI製薬
エピラス バイオファーマシューティカルズ
レオファーマ
プロビオメッド
上海医薬集団株式会社
タイプ別セグメント:
ヒュミラ
エンブレル
レミケード
シンポニー
シムジア
バイオシミラー
用途別セグメント
リウマチ関節炎
乾癬性関節炎
若年性特発性関節炎
クローン病
潰瘍性大腸炎
その他
地域別
北アメリカ
アメリカ合衆国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東およびアフリカ
トルコ
サウジアラビア
UAE（アラブ首長国連邦）
章の概要
第1章：レポートの範囲、世界の総市場規模（バルブ、ボリューム、価格）を紹介します。この章では、市場のダイナミクス、市場の最新の展開、市場の推進要因と制約要因、業界の製造業者が直面する課題とリスク、および業界の関連政策の分析も提供されます。
第2章：腫瘍壊死因子阻害薬製造業者の競争環境、価格、販売および収益市場シェア、最新の開発計画、合併および買収情報などの詳細分析です。
第3章: タイプ別のさまざまな市場セグメントの分析を提供します。それぞれの市場セグメントの市場規模と発展可能性をカバーしており、読者が異なる市場セグメントでブルーオーシャン市場を見つける手助けをします。
第4章：アプリケーション別のさまざまな市場セグメントの分析を提供し、各市場セグメントの市場規模と成長可能性をカバーし、読者が異なる下流市場でブルーオーシャン市場を見つけるのを助けます。
第5章：地域レベルでの腫瘍壊死因子阻害剤の売上と収益。各地域の市場規模と発展可能性の定量的分析を提供し、世界の各国の市場の発展、将来の発展の見通し、市場のスペース、および市場規模を紹介します。
第6章：国別の腫瘍壊死因子抑制薬の販売および収益。タイプ別および用途別に各国/地域のシグマデータを提供します。
第7章：市場の主な企業の基本状況を詳細に紹介し、主要プレイヤーのプロフィールを提供します。これには、製品の販売、収益、価格、粗利率、製品紹介、最近の開発などが含まれます。
第8章: 産業チェーンの分析、業界の上流と下流を含む。
第9章：結論。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 市場概要
1.1 腫瘍壊死因子阻害薬 : プロダクトのイントロダクション
1.2 グローバルの市場規模、市場予測
1.2.1 グローバルの腫瘍壊死因子阻害薬売上規模、金額ベース（2019年～2030年）
1.2.2 グローバルの腫瘍壊死因子阻害薬売上規模、数量ベース（2019年～2030年）
1.2.3 グローバルの腫瘍壊死因子阻害薬市場、販売価格動向（2019年～2030年）
1.3 腫瘍壊死因子阻害薬市場トレンドと成長ドライバー
1.3.1 腫瘍壊死因子阻害薬業界トレンド
1.3.2 腫瘍壊死因子阻害薬市場のドライバーと事業機会
1.3.3 腫瘍壊死因子阻害薬市場の課題
1.3.4 腫瘍壊死因子阻害薬市場の抑制要因
1.4 前提条件と限界
1.5 調査の目的
1.6 対象年
2 競合分析、企業別
2.1 グローバルの腫瘍壊死因子阻害薬、プレイヤー収益ランキング（2023年）
2.2 グローバルにおける腫瘍壊死因子阻害薬市場の収益規模、企業別（2019年～2024年）
2.3 グローバルの腫瘍壊死因子阻害薬、プレイヤー売上数量ランキング（2023年）
2.4 グローバルの腫瘍壊死因子阻害薬、売上数量（企業別）（2019年～2024年）
2.5 グローバルの腫瘍壊死因子阻害薬の平均価格、企業別（2019年～2024年）
2.6 腫瘍壊死因子阻害薬の主要メーカー、製造・販売拠点およびヘッドクオーター
2.7 腫瘍壊死因子阻害薬の主要メーカー、製品展開
2.8 腫瘍壊死因子阻害薬の主要メーカー、量産開始時期
2.9 腫瘍壊死因子阻害薬市場の競争状況分析
2.9.1 腫瘍壊死因子阻害薬市場集中度比率（2019年～2024年）
2.9.2 グローバルの腫瘍壊死因子阻害薬、上位メーカー5～10社の収益（2023年）
2.9.3 グローバルの腫瘍壊死因子阻害薬、企業タイプ別上位メーカー（Tier 1、Tier 2、Tier 3）、2023年の収益ベース
2.10 M&A、拡大
3 セグメンテーション、タイプ別
3.1 イントロダクション、タイプ別
3.1.1 ヒュミラ
3.1.2 エンブレル
3.1.3 レミケード
3.1.4 シンポニー
3.1.5 チムジア
3.1.6 バイオシミラー
3.2 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、タイプ別
3.2.1 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、タイプ別（2019年、2023年、2030年）
3.2.2 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、タイプ別（2019年～2030年）
3.2.3 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、タイプ別（%）（2019年～2030年）
3.3 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、タイプ別
3.3.1 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、タイプ別（2019年、2023年、2030年）
3.3.2 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、タイプ別（2019年～2030年）
3.3.3 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、タイプ別（%）（2019年～2030年）
3.4 グローバルの腫瘍壊死因子阻害薬の平均価格、タイプ別（2019年～2030年）
4 セグメンテーション、用途別
4.1 イントロダクション、用途別
4.1.1 関節リウマチ
4.1.2 乾癬性関節炎
4.1.3 若年性特発性関節炎
4.1.4 クローン病
4.1.5 潰よう性大腸炎
4.1.6 その他
4.2 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、用途別
4.2.1 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、用途別（2019年、2023年、2030年）
4.2.2 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、用途別（2019年～2030年）
4.2.3 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、用途別（%）（2019年～2030年）
4.3 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、用途別
4.3.1 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、用途別（2019年、2023年、2030年）
4.3.2 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、用途別（2019年～2030年）
4.3.3 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、用途別（%）（2019年～2030年）
4.4 グローバルの腫瘍壊死因子阻害薬の平均価格、用途別（2019年～2030年）
5 セグメンテーション、地域別
5.1 グローバルの腫瘍壊死因子阻害薬の売上規模、金額ベース、地域別
5.2 グローバルの腫瘍壊死因子阻害薬の売上規模、数量ベース、地域別
5.3 グローバルの腫瘍壊死因子阻害薬の平均価格、地域別（2019年～2030年）
5.4 北米
5.4.1 北米の腫瘍壊死因子阻害薬売上規模、金額ベース、2019年～2030年
5.4.2 北米の腫瘍壊死因子阻害薬の売上規模、金額ベース、国別（%）、2023年、2030年
5.5 ヨーロッパ
5.5.1 ヨーロッパの腫瘍壊死因子阻害薬売上規模、金額ベース、2019年～2030年
5.5.2 ヨーロッパの腫瘍壊死因子阻害薬の売上規模、金額ベース、国別（%）、2023年、2030年
5.6 アジア太平洋
5.6.1 アジア太平洋の腫瘍壊死因子阻害薬売上規模、金額ベース、2019年～2030年
5.6.2 アジア太平洋の腫瘍壊死因子阻害薬の売上規模、金額ベース、国別（%）、2023年、2030年
5.7 南米
5.7.1 南米の腫瘍壊死因子阻害薬売上規模、金額ベース、2019年～2030年
5.7.2 南米の腫瘍壊死因子阻害薬の売上規模、金額ベース、国別（%）、2023年、2030年
5.8 中東・アフリカ
5.8.1 中東・アフリカの腫瘍壊死因子阻害薬売上規模、金額ベース、2019年～2030年
5.8.2 中東・アフリカの腫瘍壊死因子阻害薬の売上規模、金額ベース、国別（%）、2023年、2030年
6 主要国・地域によるセグメンテーション
6.1 主要国・地域の腫瘍壊死因子阻害薬の売上成長トレンド、金額ベース（2019年、2023年、2030年）
6.2 主要国・地域の腫瘍壊死因子阻害薬の売上、金額ベース
6.3 米国
6.4 ヨーロッパ
6.5 中国
6.6 日本
6.7 韓国
6.8 東南アジア
6.9 インド
7 企業プロファイル
7.1 AbbVie Inc
7.2 Amgen Inc
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson：企業情報
7.3.2 Johnson & Johnsonの紹介と事業概要
7.3.3 Johnson & Johnson：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.3.4 Johnson & Johnson：腫瘍壊死因子阻害薬分野の提供製品
7.3.5 Johnson & Johnson直近の動向
7.4 UCB
7.4.1 UCB：企業情報
7.4.2 UCBの紹介と事業概要
7.4.3 UCB：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.4.4 UCB：腫瘍壊死因子阻害薬分野の提供製品
7.4.5 UCB直近の動向
7.5 Novartis AG
7.5.1 Novartis AG：企業情報
7.5.2 Novartis AGの紹介と事業概要
7.5.3 Novartis AG：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.5.4 Novartis AG：腫瘍壊死因子阻害薬分野の提供製品
7.5.5 Novartis AG直近の動向
7.6 Pfizer, Inc
7.7 Merck & Co\., Inc
7.8 CASI Pharmaceuticals
7.8.1 CASI Pharmaceuticals：企業情報
7.8.2 CASI Pharmaceuticalsの紹介と事業概要
7.8.3 CASI Pharmaceuticals：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.8.4 CASI Pharmaceuticals：腫瘍壊死因子阻害薬分野の提供製品
7.8.5 CASI Pharmaceuticals直近の動向
7.9 EPIRUS Biopharmaceuticals
7.9.1 EPIRUS Biopharmaceuticals：企業情報
7.9.2 EPIRUS Biopharmaceuticalsの紹介と事業概要
7.9.3 EPIRUS Biopharmaceuticals：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.9.4 EPIRUS Biopharmaceuticals：腫瘍壊死因子阻害薬分野の提供製品
7.9.5 EPIRUS Biopharmaceuticals直近の動向
7.10 LEO Pharma
7.10.1 LEO Pharma：企業情報
7.10.2 LEO Pharmaの紹介と事業概要
7.10.3 LEO Pharma：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.10.4 LEO Pharma：腫瘍壊死因子阻害薬分野の提供製品
7.10.5 LEO Pharma直近の動向
7.11 PROBIOMED
7.11.1 PROBIOMED：企業情報
7.11.2 PROBIOMEDの紹介と事業概要
7.11.3 PROBIOMED：腫瘍壊死因子阻害薬の売上、収益および売上総利益率（2019年〜2024年）
7.11.4 PROBIOMED：腫瘍壊死因子阻害薬分野の提供製品
7.11.5 PROBIOMED直近の動向
7.12 Shanghai Pharmaceuticals Holding Co\., Ltd
8 業界チェーン分析
8.1 腫瘍壊死因子阻害薬業界バリューチェーン
8.2 腫瘍壊死因子阻害薬市場の上流分析
8.2.1 主要原材料
8.2.2 原材料と主要サプライヤー
8.2.3 製造コスト構造
8.3 中流分析
8.4 下流分析（顧客についての分析）
8.5 営業販売モデル、販売チャネル
8.5.1 腫瘍壊死因子阻害薬 営業販売モデル
8.5.2 販売チャネル
8.5.3 腫瘍壊死因子阻害薬の流通業者
9 調査の結果・結論
10 付録
10.1 調査手法
10.1.1 調査手法 / 調査アプローチ
10.1.2 データソース
10.2 執筆者の詳細
10.3 免責事項
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The global market for Tumor Necrosis Factor Inhibitor Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Tumor Necrosis Factor Inhibitor Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tumor Necrosis Factor Inhibitor Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Tumor Necrosis Factor Inhibitor Drug was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Tumor Necrosis Factor Inhibitor Drug include AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB, Novartis AG, Pfizer, Inc., Merck & Co., Inc., CASI Pharmaceuticals and EPIRUS Biopharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor Inhibitor Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tumor Necrosis Factor Inhibitor Drug by region & country, by Type, and by Application.
The Tumor Necrosis Factor Inhibitor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor Inhibitor Drug.
Market Segmentation
By Company
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
UCB
Novartis AG
Pfizer, Inc.
Merck & Co., Inc.
CASI Pharmaceuticals
EPIRUS Biopharmaceuticals
LEO Pharma
PROBIOMED
Shanghai Pharmaceuticals Holding Co., Ltd.
Segment by Type:
Humira
Enbrel
Remicade
Simponi
Cimzia
Biosimilars
Segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Tumor Necrosis Factor Inhibitor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Tumor Necrosis Factor Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Tumor Necrosis Factor Inhibitor Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Tumor Necrosis Factor Inhibitor Drug Product Introduction
1.2 Global Tumor Necrosis Factor Inhibitor Drug Market Size Forecast
1.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030)
1.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume (2019-2030)
1.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Price (2019-2030)
1.3 Tumor Necrosis Factor Inhibitor Drug Market Trends & Drivers
1.3.1 Tumor Necrosis Factor Inhibitor Drug Industry Trends
1.3.2 Tumor Necrosis Factor Inhibitor Drug Market Drivers & Opportunity
1.3.3 Tumor Necrosis Factor Inhibitor Drug Market Challenges
1.3.4 Tumor Necrosis Factor Inhibitor Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tumor Necrosis Factor Inhibitor Drug Players Revenue Ranking (2023)
2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2019-2024)
2.3 Global Tumor Necrosis Factor Inhibitor Drug Players Sales Volume Ranking (2023)
2.4 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Company Players (2019-2024)
2.5 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Tumor Necrosis Factor Inhibitor Drug
2.9 Tumor Necrosis Factor Inhibitor Drug Market Competitive Analysis
2.9.1 Tumor Necrosis Factor Inhibitor Drug Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Tumor Necrosis Factor Inhibitor Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitor Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Humira
3.1.2 Enbrel
3.1.3 Remicade
3.1.4 Simponi
3.1.5 Cimzia
3.1.6 Biosimilars
3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type
3.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Value, by Type (2019-2030)
3.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type
3.3.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Psoriatic Arthritis
4.1.3 Juvenile Idiopathic Arthritis
4.1.4 Crohn’s Disease
4.1.5 Ulcerative Colitis
4.1.6 Others
4.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application
4.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Value, by Application (2019-2030)
4.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application
4.3.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region
5.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2019-2024)
5.1.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2025-2030)
5.1.4 Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (%), (2019-2030)
5.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region
5.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2019-2024)
5.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2025-2030)
5.2.4 Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
5.4.2 North America Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
5.5.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
5.7.2 South America Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value
6.2.1 Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.3.2 United States Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.4.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.5.2 China Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.6.2 Japan Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.7.2 South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019-2030
6.9.2 India Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Tumor Necrosis Factor Inhibitor Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Company Information
7.1.2 AbbVie Inc. Introduction and Business Overview
7.1.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.1.5 AbbVie Inc. Recent Development
7.2 Amgen Inc.
7.2.1 Amgen Inc. Company Information
7.2.2 Amgen Inc. Introduction and Business Overview
7.2.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.2.5 Amgen Inc. Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Information
7.3.2 Johnson & Johnson Introduction and Business Overview
7.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.3.5 Johnson & Johnson Recent Development
7.4 UCB
7.4.1 UCB Company Information
7.4.2 UCB Introduction and Business Overview
7.4.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.4.4 UCB Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.4.5 UCB Recent Development
7.5 Novartis AG
7.5.1 Novartis AG Company Information
7.5.2 Novartis AG Introduction and Business Overview
7.5.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.5.5 Novartis AG Recent Development
7.6 Pfizer, Inc.
7.6.1 Pfizer, Inc. Company Information
7.6.2 Pfizer, Inc. Introduction and Business Overview
7.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.6.5 Pfizer, Inc. Recent Development
7.7 Merck & Co., Inc.
7.7.1 Merck & Co., Inc. Company Information
7.7.2 Merck & Co., Inc. Introduction and Business Overview
7.7.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.7.5 Merck & Co., Inc. Recent Development
7.8 CASI Pharmaceuticals
7.8.1 CASI Pharmaceuticals Company Information
7.8.2 CASI Pharmaceuticals Introduction and Business Overview
7.8.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.8.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.8.5 CASI Pharmaceuticals Recent Development
7.9 EPIRUS Biopharmaceuticals
7.9.1 EPIRUS Biopharmaceuticals Company Information
7.9.2 EPIRUS Biopharmaceuticals Introduction and Business Overview
7.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.9.5 EPIRUS Biopharmaceuticals Recent Development
7.10 LEO Pharma
7.10.1 LEO Pharma Company Information
7.10.2 LEO Pharma Introduction and Business Overview
7.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.10.4 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.10.5 LEO Pharma Recent Development
7.11 PROBIOMED
7.11.1 PROBIOMED Company Information
7.11.2 PROBIOMED Introduction and Business Overview
7.11.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.11.4 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.11.5 PROBIOMED Recent Development
7.12 Shanghai Pharmaceuticals Holding Co., Ltd.
7.12.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
7.12.2 Shanghai Pharmaceuticals Holding Co., Ltd. Introduction and Business Overview
7.12.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Offerings
7.12.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Development
8 Industry Chain Analysis
8.1 Tumor Necrosis Factor Inhibitor Drug Industrial Chain
8.2 Tumor Necrosis Factor Inhibitor Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tumor Necrosis Factor Inhibitor Drug Sales Model
8.5.2 Sales Channel
8.5.3 Tumor Necrosis Factor Inhibitor Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Tumor Necrosis Factor Inhibitor Drug Market Trends Table 2. Tumor Necrosis Factor Inhibitor Drug Market Drivers & Opportunity Table 3. Tumor Necrosis Factor Inhibitor Drug Market Challenges Table 4. Tumor Necrosis Factor Inhibitor Drug Market Restraints Table 5. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company (2019-2024) Table 7. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Company (2019-2024) & (K Units) Table 8. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume Market Share by Company (2019-2024) Table 9. Global Market Tumor Necrosis Factor Inhibitor Drug Price by Company (2019-2024) & (US$/Unit) Table 10. Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Manufacturing Base Distribution and Headquarters Table 11. Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Product Type Table 12. Key Manufacturers Time to Begin Mass Production of Tumor Necrosis Factor Inhibitor Drug Table 13. Global Tumor Necrosis Factor Inhibitor Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitor Drug as of 2023) Table 15. Mergers & Acquisitions, Expansion Plans Table 16. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 17. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (2019-2024) & (US$ Million) Table 18. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (2025-2030) & (US$ Million) Table 19. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Value by Type (2019-2024) & (%) Table 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Value by Type (2025-2030) & (%) Table 21. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units) Table 22. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type (2019-2024) & (K Units) Table 23. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type (2025-2030) & (K Units) Table 24. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Volume by Type (2019-2024) & (%) Table 25. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Volume by Type (2025-2030) & (%) Table 26. Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2019-2024) & (US$/Unit) Table 27. Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2025-2030) & (US$/Unit) Table 28. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 29. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (2019-2024) & (US$ Million) Table 30. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (2025-2030) & (US$ Million) Table 31. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Value by Application (2019-2024) & (%) Table 32. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Value by Application (2025-2030) & (%) Table 33. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units) Table 34. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application (2019-2024) & (K Units) Table 35. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application (2025-2030) & (K Units) Table 36. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Volume by Application (2019-2024) & (%) Table 37. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share in Volume by Application (2025-2030) & (%) Table 38. Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2019-2024) & (US$/Unit) Table 39. Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2025-2030) & (US$/Unit) Table 40. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 41. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2019-2024) & (US$ Million) Table 42. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2025-2030) & (US$ Million) Table 43. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2019-2024) & (%) Table 44. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Region (2025-2030) & (%) Table 45. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030 Table 46. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2019-2024) & (K Units) Table 47. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2025-2030) & (K Units) Table 48. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2019-2024) & (%) Table 49. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Region (2025-2030) & (%) Table 50. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2019-2024) & (US$/Unit) Table 51. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2025-2030) & (US$/Unit) Table 52. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 53. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2024) & (US$ Million) Table 54. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value, (2025-2030) & (US$ Million) Table 55. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Volume, (2019-2024) & (K Units) Table 56. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Volume, (2025-2030) & (K Units) Table 57. AbbVie Inc. Company Information Table 58. AbbVie Inc. Introduction and Business Overview Table 59. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 60. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 61. AbbVie Inc. Recent Development Table 62. Amgen Inc. Company Information Table 63. Amgen Inc. Introduction and Business Overview Table 64. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 65. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 66. Amgen Inc. Recent Development Table 67. Johnson & Johnson Company Information Table 68. Johnson & Johnson Introduction and Business Overview Table 69. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 70. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 71. Johnson & Johnson Recent Development Table 72. UCB Company Information Table 73. UCB Introduction and Business Overview Table 74. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 75. UCB Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 76. UCB Recent Development Table 77. Novartis AG Company Information Table 78. Novartis AG Introduction and Business Overview Table 79. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 80. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 81. Novartis AG Recent Development Table 82. Pfizer, Inc. Company Information Table 83. Pfizer, Inc. Introduction and Business Overview Table 84. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 85. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 86. Pfizer, Inc. Recent Development Table 87. Merck & Co., Inc. Company Information Table 88. Merck & Co., Inc. Introduction and Business Overview Table 89. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 90. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 91. Merck & Co., Inc. Recent Development Table 92. CASI Pharmaceuticals Company Information Table 93. CASI Pharmaceuticals Introduction and Business Overview Table 94. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 95. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 96. CASI Pharmaceuticals Recent Development Table 97. EPIRUS Biopharmaceuticals Company Information Table 98. EPIRUS Biopharmaceuticals Introduction and Business Overview Table 99. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 100. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 101. EPIRUS Biopharmaceuticals Recent Development Table 102. LEO Pharma Company Information Table 103. LEO Pharma Introduction and Business Overview Table 104. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 105. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 106. LEO Pharma Recent Development Table 107. PROBIOMED Company Information Table 108. PROBIOMED Introduction and Business Overview Table 109. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 110. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 111. PROBIOMED Recent Development Table 112. Shanghai Pharmaceuticals Holding Co., Ltd. Company Information Table 113. Shanghai Pharmaceuticals Holding Co., Ltd. Introduction and Business Overview Table 114. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024) Table 115. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Offerings Table 116. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Development Table 117. Key Raw Materials Lists Table 118. Raw Materials Key Suppliers Lists Table 119. Tumor Necrosis Factor Inhibitor Drug Downstream Customers Table 120. Tumor Necrosis Factor Inhibitor Drug Distributors List Table 121. Research Programs/Design for This Report Table 122. Key Data Information from Secondary Sources Table 123. Key Data Information from Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Inhibitor Drug Product Picture Figure 2. Global Tumor Necrosis Factor Inhibitor Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume (2019-2030) & (K Units) Figure 5. Global Tumor Necrosis Factor Inhibitor Drug Sales Price (2019-2030) & (US$/Unit) Figure 6. Tumor Necrosis Factor Inhibitor Drug Report Years Considered Figure 7. Global Tumor Necrosis Factor Inhibitor Drug Players Revenue Ranking (2023) & (US$ Million) Figure 8. Global Tumor Necrosis Factor Inhibitor Drug Players Sales Volume Ranking (2023) & (K Units) Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Tumor Necrosis Factor Inhibitor Drug Revenue in 2023 Figure 10. Tumor Necrosis Factor Inhibitor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 11. Humira Picture Figure 12. Enbrel Picture Figure 13. Remicade Picture Figure 14. Simponi Picture Figure 15. Cimzia Picture Figure 16. Biosimilars Picture Figure 17. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Sales Value Market Share by Type, 2023 & 2030 Figure 19. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units) Figure 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume Market Share by Type, 2023 & 2030 Figure 21. Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2019-2030) & (US$/Unit) Figure 22. Product Picture of Rheumatoid Arthritis Figure 23. Product Picture of Psoriatic Arthritis Figure 24. Product Picture of Juvenile Idiopathic Arthritis Figure 25. Product Picture of Crohn’s Disease Figure 26. Product Picture of Ulcerative Colitis Figure 27. Product Picture of Others Figure 28. Global Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 29. Global Tumor Necrosis Factor Inhibitor Drug Sales Value Market Share by Application, 2023 & 2030 Figure 30. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units) Figure 31. Global Tumor Necrosis Factor Inhibitor Drug Sales Volume Market Share by Application, 2023 & 2030 Figure 32. Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2019-2030) & (US$/Unit) Figure 33. North America Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 34. North America Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030 Figure 35. Europe Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 36. Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030 Figure 37. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 38. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030 Figure 39. South America Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 40. South America Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030 Figure 41. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Value (2019-2030) & (US$ Million) Figure 42. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Value by Country (%), 2023 VS 2030 Figure 43. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Value (%), (2019-2030) Figure 44. Key Countries/Regions Tumor Necrosis Factor Inhibitor Drug Sales Volume (%), (2019-2030) Figure 45. United States Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 46. United States Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 47. United States Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 48. Europe Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 49. Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 50. Europe Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 51. China Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 52. China Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 53. China Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 54. Japan Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 55. Japan Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 56. Japan Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 57. South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 58. South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 59. South Korea Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 60. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 61. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 62. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 63. India Tumor Necrosis Factor Inhibitor Drug Sales Value, (2019-2030) & (US$ Million) Figure 64. India Tumor Necrosis Factor Inhibitor Drug Sales Value by Type (%), 2023 VS 2030 Figure 65. India Tumor Necrosis Factor Inhibitor Drug Sales Value by Application (%), 2023 VS 2030 Figure 66. Tumor Necrosis Factor Inhibitor Drug Industrial Chain Figure 67. Tumor Necrosis Factor Inhibitor Drug Manufacturing Cost Structure Figure 68. Channels of Distribution (Direct Sales, and Distribution) Figure 69. Bottom-up and Top-down Approaches for This Report Figure 70. Data Triangulation Figure 71. Key Executives Interviewed
